👨⚕️ Lucentis is a prescription medicine used to treat eye diseases like wet age-related macular degeneration.
💼 The deal includes the acquisition of commercial rights and inventory of Lucentis in the US.
🌍 Sandoz aims to enhance access to affordable ophthalmology treatments for patients worldwide.
🏥 Lucentis generated annual US sales of approximately $1.7 billion in 2019.
Introduction:
Sandoz, the generics division of Novartis, has acquired the US rights to Coherus BioSciences’ Lucentis biosimilar for $170 million. Lucentis is a treatment for retinal diseases and has generated sales of $1.7 billion in the US. This acquisition expands Sandoz’s ophthalmology portfolio and strengthens its position as a global leader in biosimilars.
- The US rights to Coherus BioSciences’ Lucentis biosimilar have been acquired by Sandoz for $170 million.
- Lucentis is a treatment for retinal diseases and has generated $1.7 billion in US sales.
- This acquisition expands Sandoz’s ophthalmology portfolio and strengthens its position in the biosimilars market.
- Sandoz aims to improve patient access to affordable, high-quality treatments through its biosimilar portfolio.
- The acquisition demonstrates the growing demand for biosimilars and the potential for cost savings in the healthcare industry.
Conclusion:
Sandoz’s acquisition of Coherus BioSciences’ Lucentis biosimilar for $170 million expands its ophthalmology portfolio and strengthens its position in the biosimilars market. This acquisition highlights the increasing demand for biosimilars and the potential for cost savings in the healthcare industry. Through its biosimilar portfolio, Sandoz aims to improve patient access to affordable, high-quality treatments.
